Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1634 1635 1636 1643 1656
This examiner grants 56% of resolved cases
Alexandra Geraldine Dace Denito, in Tech Center 1600 and Art Unit 1633, has 64 resolved cases. Her allowance rate is 56.3%, and the median days to allowance is 1340. The interview lift of 40.2% is high, indicating that interviews are a tool for increasing the 56.3% allowance rate. This 40.2% lift is a key factor for the 64 resolved cases analyzed in her docket.
Practitioners should prepare for a 1340-day timeline when working with this examiner in Tech Center 1600. The 40.2% lift from interviews suggests that verbal advocacy can improve the 56.3% baseline success rate. For the 64 resolved cases, the 1340-day median pendency reflects the pace of examination. Using the 40.2% lift is a path to overcoming hurdles and securing a patent grant in Art Unit 1633. These metrics define the prosecution environment under her review.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17788519 | IMMUNOTHERAPY FOR DIRECT REPROGRAMMING OF CANCER CELLS INTO IMMUNE CELLS/ANTIGEN PRESENTING CELLS/DENDRITIC CELLS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18094695 | OLIGONUCLEOTIDES FOR MECP2 MODULATION | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 18420013 | METHOD FOR DIAGNOSING DRUG ADDICTION, METHOD FOR SCREENING THERAPEUTIC AGENT FOR DRUG ADDICTION AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DRUG ADDICTION | Final Rejection | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17257796 | RETROTRANSPOSON-BASED DELIVERY VEHICLE AND METHODS OF USE THEREOF | Final Rejection | The Regents of the University of California |
| 18582620 | METHODS AND MEANS FOR ENHANCING RNA PRODUCTION | Non-Final OA | CureVac Manufacturing GmbH |
| 16820590 | NON-NATURALLY OCCURRING CAPSIDS FOR DELIVERY OF NUCLEIC ACIDS AND/OR PROTEINS | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18763490 | METHODS AND COMPOSITIONS FOR MODIFYING A TARGETED LOCUS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17413297 | ANELLOSOMES FOR DELIVERING PROTEIN REPLACEMENT THERAPEUTIC MODALITIES | Final Rejection | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 18279169 | PRODUCTS AND METHODS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIES USING CRISPR-CAS9 TO CORRECT DMD EXON DUPLICATIONS | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17842891 | HAIRPIN STRUCTURE NUCLEIC ACID MOLECULES CAPABLE OF MODULATING TARGET GENE EXPRESSION AND USES THEREOF | Final Rejection | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17614795 | METHOD FOR INHIBITING INFECTION AND ACTIVATION OF VIRUS | Non-Final OA | INSTITUTE FOR BASIC SCIENCE |
| 18688475 | COMPOSITION AND METHOD TO TREAT CACHEXIA | Non-Final OA | THE TRUSTEES OF INDIANA UNIVERSITY |
| 18269141 | TREATMENT FOR LYSINE DEGRADATION-ASSOCIATED DISORDERS | Non-Final OA | UCL BUSINESS LTD |
| 17942951 | GROUND MEAT REPLICAS | Non-Final OA | Impossible Foods Inc. |
| 17378274 | HUMAN MIRNAS FOR USE IN DIAGNOSIS, PROGNOSIS, AND THERAPY OF HUMAN CONDITIONS AND DISEASES | Final Rejection | THOMAS JEFFERSON UNIVERSITY |
| 17277397 | COMPOSITIONS AND METHODS FOR MODULATION OF LMNA EXPRESSION | Final Rejection | THE UNITED STATES OF AMERICA , AS REPRESENTED BY THE SECRETARY , DEPARTMENT OF HEALTH AND HUMAN SERV |
| 17497725 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | Non-Final OA | ARBOR BIOTECHNOLOGIES, INC. |
| 17788524 | BODY FAT REDUCING AGENT AND METHOD FOR SCREENING FOR SUBSTANCE CAPABLE OF REDUCING BODY FAT | Non-Final OA | INNATE CELL THERAPY INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy